Certolizumab Pegol Reduced Anterior Uveitis Flares Compared With Standard Non‐Biologic Treatment: Results From an Overlap Weighting Analysis in High‐Risk Patients With Axial Spondyloarthritis

Key Points

• The aim is to evaluate the effectiveness of certolizumab pegol in reducing anterior uveitis flares compared to standard non-biologic treatment in high-risk patients with axial spondyloarthritis.
• Conducted an overlap weighting analysis
• Compared certolizumab pegol with standard non-biologic treatment
• Focused on high-risk patients with axial spondyloarthritis
• Certolizumab pegol significantly reduced the frequency of anterior uveitis flares
• Improved clinical outcomes compared to standard treatment
• Supported previous findings from the C-VIEW study